A Systematic Review of the Diagnostic Role of BRAF V600E Testing in Thyroid Nodules with Atypia of Undetermined Significance.
메타분석
1/5 보강
The BRAF V600E mutation is a key molecular marker for malignancy in thyroid nodules showing cytological features of atypia of undetermined significance (AUS).
APA
Saleem N, Robbins M, et al. (2025). A Systematic Review of the Diagnostic Role of BRAF V600E Testing in Thyroid Nodules with Atypia of Undetermined Significance.. Cureus, 17(8), e90292. https://doi.org/10.7759/cureus.90292
MLA
Saleem N, et al.. "A Systematic Review of the Diagnostic Role of BRAF V600E Testing in Thyroid Nodules with Atypia of Undetermined Significance.." Cureus, vol. 17, no. 8, 2025, pp. e90292.
PMID
40970023 ↗
Abstract 한글 요약
The BRAF V600E mutation is a key molecular marker for malignancy in thyroid nodules showing cytological features of atypia of undetermined significance (AUS). It is strongly associated with papillary thyroid carcinoma (PTC), improves diagnostic accuracy and clinical management stratification, and serves as a significant risk factor of malignancy (ROM) when combined with identifying aggressive features such as lymph node metastases and extra-thyroid extension. This systematic literature review examines the diagnostic role of the BRAF V600E mutation in AUS nodules, emphasizing its integration with cytological evaluation, ultrasound-based risk stratification systems (US-RSS), and cytological subclassification. Selective BRAF testing improves sensitivity and specificity, optimizing resource utilization while reducing unnecessary surgeries. Incorporation of this mutation into multigene classifiers, such as ThyroSeq v3, further supports cost-effective and personalized management strategies for indeterminate thyroid nodules. By combining molecular and imaging data, BRAF V600E testing plays a pivotal role in advancing thyroid cancer diagnosis and treatment. It enhances malignancy risk stratification and facilitates precise clinical decision-making, leading to improved patient outcomes.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Dual targeting of BRAF and ferroptosis results in synergistic anticancer activity via iron overload and enhanced oxidative stress.
- Decoding the Mutational Hierarchy of Thyroid Cancer and Associated Signaling Pathways.
- Unveiling a BRAF Signature Proficient in Accurately Capturing Oncogenic Activity and Guiding Prognostic Prediction Across Multiple Cancers.
- Superior efficacy of vemurafenib combined with iodine-131 for lymph node metastatic BRAF-mutant thyroid cancer: a long-term survival analysis.
- A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus nivolumab.
- Distinct clinical and genomic profiles of braf mutation subtypes in Chinese colorectal cancer: a retrospective cohort study with cross-population validation.